Clinical trial
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
ClinicalTrials.gov ID: NCT01668784
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb (Responsible Party)
Last Update Posted: 2022-08-09
Brief Summary:
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Official Title:
A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Intervention / Treatment:
- Biological: Nivolumab
- Drug: Everolimus
| Category | Value |
|---|---|
| Study Start (Actual) | 2012-10-09 |
| Primary Completion (Actual) | 2015-05-06 |
| Study Completion (Actual) | 2021-07-19 |
| Enrollment (Actual) | 821 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
CA209-025
2011-005132-26 (EudraCT Number) |